Literature DB >> 2969000

Altered metabolic and hormonal responses to epinephrine and beta-endorphin in human obesity.

D Giugliano1, D Cozzolino, T Salvatore, R Torella, P Franchimont, F D'Onofrio, P J Lefebvre.   

Abstract

Catecholamines and endogenous opioid peptides are released in response to stress. Exogenous infusions of epinephrine and beta-endorphin (both in doses of 15, 50, and 80 ng/kg.min sequentially, each dose lasting 30 min) were used to mimic short term stress in both normal weight (body mass index, less than 25 kg/m2) and obese (body mass index, greater than 30 kg/m2) subjects. Fasting plasma insulin, C-peptide, and beta-endorphin concentrations were significantly higher in the obese than in the normal subjects (P less than 0.01-0.005). In lean subjects epinephrine produced significant increases in plasma glucose levels, but no appreciable changes in plasma insulin, C-peptide, or glucagon. Infusion of beta-endorphin in the same subjects caused plasma glucose and glucagon to rise, but insulin and C-peptide levels did not change. The simultaneous infusion of epinephrine and beta-endorphin produced a glycemic response which, although greater, was not significantly different than the sum of the responses to the individual hormone infusions. However, the two hormones had a synergistic interaction on plasma glucagon levels [total glucagon response, 2275 +/- 370 pg/min.mL (ng/min.L); sum of single effects, 750 +/- 152 (+/- SE) pg/min.mL (ng/min.L); P less than 0.01]. The plasma epinephrine [207 +/- 21, 607 +/- 70, and 1205 +/- 134 pg/mL (1130 +/- 115, 3640 +/- 382, and 6577 +/- 691 pmol/L] and beta-endorphin [875 +/- 88, 1250 +/- 137, and 1562 +/- 165 pg/mL (250 +/- 25, 358 +/- 39, and 447 +/- 47 pmol/L] concentrations attained during the infusions of each single hormone were not different from those recorded during the combined hormonal infusion. In obese subjects epinephrine raised plasma glucose levels and caused dose-related increments of plasma glucagon concentrations. Plasma insulin and C-peptide concentrations remained low and rebounded at the end of the infusions. In the same subjects, beta-endorphin produced elevations of plasma glucose, insulin, C-peptide, and glucagon. When the combined hormonal infusion was given to obese subjects, the plasma epinephrine and beta-endorphin concentrations rose to values not significantly different from those in normal weight subjects. However, there was a dramatic increase in plasma glucose exceeding 200 mg/dL (11.1 mmol/L), which remained elevated 30 min after the infusion. The glucagon response was not greater than the sum of the single effects.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969000     DOI: 10.1210/jcem-67-2-238

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.

Authors:  S Balon-Perin; J Kolanowski; A Berbinschi; P Franchimont; J M Ketelslegers
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

Review 2.  The Clash of Two Epidemics: the Relationship Between Opioids and Glucose Metabolism.

Authors:  Laura L Koekkoek; Luna L van der Gun; Mireille J Serlie; Susanne E la Fleur
Journal:  Curr Diab Rep       Date:  2022-05-20       Impact factor: 5.430

3.  Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

Authors:  D Giugliano; A Quatraro; G Consoli; A Minei; A Ceriello; N De Rosa; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks.

Authors:  Nikolai Jaschke; Sophie Pählig; Ying-Xian Pan; Lorenz C Hofbauer; Andy Göbel; Tilman D Rachner
Journal:  Trends Endocrinol Metab       Date:  2021-03-03       Impact factor: 12.015

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.